07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

ReoPro abciximab: Postmarketing study data

The single-blind, international postmarketing INFUSE-AMI trial in 452 patients with ST-segment-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) showed that a 0.25 mg/kg bolus of intracoronary ReoPro administered at the site of the infarct...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Atrium Medical, Getinge deal

Getinge will acquire cardiovascular company Atrium Medical for $680 million in cash. Atrium will operate as an independent business unit under Getinge's Maquet Cardiovascular subsidiary and Trevor Carlton will remain president. Getinge said it would...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Clinical News

ReoPro abciximab: Phase IV started

Atrium Medical Corp. (Hudson, N.H.) began a single-blind, international post-marketing study to evaluate percutaneous coronary intervention (standard of care), intracoronary (IC) infusion of ReoPro via its ClearWay RX catheter; and thrombus aspiration alone or followed...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Isotechnika Inc., Atrium Medical deal

Atrium received an exclusive worldwide license to develop and commercialize ISA's TAFA93 and ISA247 compounds with drug-eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders. ISA will receive a $3...